Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Financial Sense Advisors Inc.

Financial Sense Advisors Inc. reduced its position in Edwards Lifesciences Co. (NYSE:EW) by 33.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,600 shares of the medical research company’s stock after selling 3,300 shares during the quarter. Financial Sense Advisors Inc.’s holdings in Edwards Lifesciences were worth $489,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Private Advisor Group LLC increased its stake in Edwards Lifesciences by 79.4% during the 4th quarter. Private Advisor Group LLC now owns 21,326 shares of the medical research company’s stock worth $1,579,000 after buying an additional 9,440 shares during the period. Pegasus Asset Management Inc. grew its stake in shares of Edwards Lifesciences by 0.4% in the fourth quarter. Pegasus Asset Management Inc. now owns 42,628 shares of the medical research company’s stock worth $3,156,000 after acquiring an additional 159 shares in the last quarter. Venturi Wealth Management LLC raised its stake in shares of Edwards Lifesciences by 1,013.3% in the fourth quarter. Venturi Wealth Management LLC now owns 2,683 shares of the medical research company’s stock valued at $199,000 after acquiring an additional 2,442 shares in the last quarter. D.A. Davidson & CO. boosted its holdings in Edwards Lifesciences by 3.1% in the fourth quarter. D.A. Davidson & CO. now owns 10,033 shares of the medical research company’s stock valued at $743,000 after purchasing an additional 300 shares during the period. Finally, Empower Advisory Group LLC grew its stake in Edwards Lifesciences by 9.9% during the 4th quarter. Empower Advisory Group LLC now owns 775,563 shares of the medical research company’s stock worth $57,415,000 after purchasing an additional 69,685 shares in the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Down 1.2 %

EW stock opened at $74.73 on Thursday. The company has a market cap of $44.07 billion, a price-to-earnings ratio of 10.72, a price-to-earnings-growth ratio of 4.92 and a beta of 1.10. The company has a fifty day moving average price of $72.84 and a 200 day moving average price of $69.82. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Sell-side analysts expect that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the sale, the vice president now owns 23,189 shares of the company’s stock, valued at $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the transaction, the chief financial officer now directly owns 30,561 shares of the company’s stock, valued at $2,315,301.36. This represents a 26.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 26,489 shares of company stock valued at $2,002,829 in the last ninety days. Insiders own 1.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on EW shares. Daiwa America lowered Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Canaccord Genuity Group raised their target price on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a report on Thursday, February 13th. Evercore ISI lowered their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a report on Wednesday, February 12th. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their price objective for the company from $75.00 to $90.00 in a report on Thursday, January 30th. Finally, Sanford C. Bernstein upgraded shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.